In a nutshell
Da Volterra is a private clinical-stage biopharmaceutical company which innovates for better health and care for people worldwide.
Our team is composed of 45 people with an extensive experience in science and in the industrial development of medical products. Together, we are dedicated to developing novel and safe therapeutic options for patients.
Our expertise focuses on the protection of the intestinal microbiome during antibiotic treatments.
- Based in Paris, France
- 45 collaborators,
- 70M€ funds raised
- Lead Microbiome Protector
in Phase 3
Da Volterra’s goal is to develop and commercialize innovative healthcare solutions to preserve the intestinal microbiome of patients worldwide and help prevent and cure life-threatening diseases.
As new insights into the human intestinal microbiome are fundamentally reshaping how we understand and treat a wide range of diseases, Da Volterra is a pioneer in understanding and harnessing the microbiome capacity to help prevent and cure diseases.
The company’s most advanced asset is DAV132, an oral product designed to be co-administered with any antibiotic, in order to protect patients from antibiotic-induced disruption of the intestinal microbiome.